ArticleVaccine2022
Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review.Frontiers in immunology · 2022Pooled it
- High-Dose vs. Standard-Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU-1.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- [Inflammatory rheumatic diseases in patients with post-COVID syndrome].Zeitschrift fur Rheumatologie · 2026Article
- Article
- Impact of obesity on COVID-19 CoronaVac and ChAdOx1-S vaccine efficacy.BMC infectious diseases · 2025Article
- Article
- A scoping review: the impact of nutritional status on the efficacy, effectiveness, and immunogenicity of COVID-19 vaccines.Tropical diseases, travel medicine and vaccines · 2025Review
- Article
- Neutralizing antibody responses to three XBB protein vaccines in older adults.Signal transduction and targeted therapy · 2025Article
- Reduced immune response to SARS-CoV-2 infection in the elderly after 6 months.Frontiers in immunology · 2025Article
- SARS-CoV-2 Infection Risk by Vaccine Doses and Prior Infections Over 24 Months: ProHEpiC-19 Longitudinal Study.JMIR public health and surveillance · 2024Article
- Article
- COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.Vaccine: X · 2024Review
- How does geographical diversity shape vaccine efficacy?Clinical and experimental vaccine research · 2024Review
- Article
- The Protection Level of S-RBD SARS-CoV-2 Immunoglobulin G Antibodies Using the Chemiluminescent Immunoassay Compared to the Surrogate Virus Neutralization Test Method.Diagnostics (Basel, Switzerland) · 2024Article
- More severe comorbidities, advanced age, and incomplete vaccination increase the risk of COVID-19 mortality.Narra J · 2024Article
- SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series.Scientific reports · 2024Article
- Characteristics Associated with COVID-19 Breakthrough Infections after Booster Vaccinations in Healthcare Workers: Insights from the TüSeRe:exact Study.Journal of clinical medicine · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several types of vaccines have been developed to prevent the coronavirus disease 2019 (COVID-19). It is important to understand whether demographic and clinical variables affect the effectiveness of various types of vaccines. This study analysed the association between demographic/clinical factors, antibody response and vaccine effectiveness in healthcare workers vaccinated with inactivated virus. We enrolled 101 healthcare workers who received two doses of inactivated viral vaccine (CoronaVac). Blood samples were analysed at 1, 3, and 5 months after the second dose of vaccination. Data regarding demographic characteristics, medical histories, and clinical parameters were collected by interview and medical examination. In a separate retrospective study, we analysed the incidence of vaccine breakthrough infection on 2714 healthcare workers who received two doses of inactivated viral vaccine. Medical histories and demographic data were collected using a structured self-reported questionnaire. We found that antibody titres markedly increased at 1 month after vaccination but gradually decreased at 3-5 months post-vaccination. We observed a significant association between age (≥40 years) and antibody level, whereas sex and body mass index (BMI) exhibited no effect on antibody titres. Amongst clinical variables analysed, high blood pressure and history of hypertension were significantly correlated with lower antibody titres. Consistently, we found a significant association in the retrospective study between hypertension and the incidence of breakthrough infection. In conclusion, our results showed that hypertension is associated with lower antibody titres and breakthrough infection following COVID-19 vaccination. Thus, blood pressure control might be important to improve the efficacy of inactivated virus vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.